Recent Quotes
My Watchlist
Indicators
OGJ 150 Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

109.45 +0.62 (+0.57%)
Official Closing Price Updated: 4:10 PM EST, Jan 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,909,869
Open 108.11
Bid (Size) 108.80 (100)
Ask (Size) 109.70 (300)
Prev. Close 108.83
Today's Range 106.93 - 109.64
52wk Range 73.31 - 112.90
Shares Outstanding 2,531,374,696
Dividend Yield 3.11%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update ↗
Intismeran autogene vaccine, in combination with cancer drug Keytruda, reduced the risk of recurrence or death at five years of follow-up, the company said. 
Via Stocktwits
News headline image
GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics
In a bold strategic opening to the 2026 fiscal year, pharmaceutical giant GSK (NYSE:GSK) has announced a definitive agreement to acquire RAPT Therapeutics (Nasdaq:RAPT) for approximately $2.2 billion.... 
Via MarketMinute
Topics Intellectual Property

Performance

YTD
+2.8%
+2.8%
1 Month
+4.5%
+4.5%
3 Month
+26.8%
+26.8%
6 Month
+38.0%
+38.0%
1 Year
+13.7%
+13.7%

More News

Read More
News headline image
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following
Via ACCESS Newswire
ABUS Stock On Track For Biggest Intraday Drop In Over 5 Years – What’s The Issue Around Its Patent In Europe? ↗
Via Stocktwits
Topics Intellectual Property
Merck & Co. Inc. (NYSE:MRK) Presents a Compelling Value Investment Case ↗
Via Chartmill
Merck In Talks To Acquire Revolution Medicines For About $30B: Report ↗
Via Stocktwits
News headline image
3 “Forever Stocks” to Hold When the Market Won’t Sit Still ↗
Via MarketBeat
News headline image
The New Era of Johnson & Johnson: A 2026 Deep-Dive Research Feature
Via Finterra
Topics Artificial Intelligence Bankruptcy Economy
News headline image
3 Profitable Stocks to Consider Right Now
Via StockStory
News headline image
The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026
Via Finterra
Topics Initial Public Offering Intellectual Property Lawsuit
News headline image
2 Unpopular Stocks That Should Get More Attention and 1 We Brush Off
Via StockStory
News headline image
The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Healthcare Titan Ascendant: Johnson & Johnson Hits All-Time Highs as It Navigates a New Political and Clinical Era
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Earnings
A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗
Via Chartmill
News headline image
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B ↗
Via Stocktwits
News headline image
The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
3 Dividend Stocks to Hold for the Next 10 Years ↗
Via The Motley Fool
Topics Bonds
News headline image
1 Momentum Stock Worth Your Attention and 2 Facing Headwinds
Via StockStory
News headline image
This ETF Is Proof That the Healthcare Rebound Is Real ↗
Via MarketBeat
Topics ETFs
News headline image
Why Revolution Medicines Stock Surged by 11% Today ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation
Via MarketMinute
Topics Intellectual Property
News headline image
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
Via PredictStreet
Topics Initial Public Offering Intellectual Property
News headline image
Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight ↗
Via Benzinga

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 109.45
When was Merck & Co last traded?
The last trade of Merck & Co was at 01/20/26 04:10 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 277.06B
How many shares of Merck & Co are outstanding?
Merck & Co has 277B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>